End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.47 CNY | +3.26% | +5.29% | +27.28% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+27.28% | 2.88B | D- | ||
+43.38% | 749B | C+ | ||
+39.42% | 605B | B | ||
-6.46% | 351B | C+ | ||
+19.58% | 328B | B- | ||
+8.75% | 292B | C+ | ||
+11.92% | 216B | B- | ||
-2.62% | 214B | A+ | ||
+0.36% | 167B | C+ | ||
+6.49% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002773 Stock
- Ratings Chengdu Kanghong Pharmaceutical Group Co., Ltd